Precisionsmedicin för cancer – Olli Kallioniemis forskargrupp

En del av:

Institutionen för onkologi-patologi

Start
Publikationer
Medarbetare och kontakt

Publikationer

Utvalda publikationer

Article: LEUKEMIA. 2017;31(5):1048-1058
Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia
Ojamies P; Kontro M; Edgren H; Ellonen P; Lagstrom S; Almusa H; Miettinen T; Eldfors S; Tamborero D; Wennerberg K; Heckman C; Porkka K; Wolf M; Kallioniemi O
Article: LEUKEMIA. 2017;31(5):1187-1195
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
Malani D; Murumagi A; Yadav B; Kontro M; Eldfors S; Kumar A; Karjalainen R; Majumder MM; Ojamies P; Pemovska T; Wennerberg K; Heckman C; Porkka K; Wolf M; Aittokallio T; Kallioniemi O
Article: EUROPEAN UROLOGY. 2017;71(3):319-327
Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer
Saeed K; Rahkama V; Eldfors S; Bychkov D; Mpindi JP; Yadav B; Paavolainen L; Aittokallio T; Heckman C; Wennerberg K; Peehl DM; Horvath P; Mirtti T; Rannikko A; Kallioniemi O; Ostling P; af Hallstrom TM
Letter: NATURE. 2016;540(7631):E5-E6
Consistency in drug response profiling
Mpindi JP; Yadav B; Ostling P; Gautam P; Malani D; Murumagi A; Hirasawa A; Kangaspeska S; Wennerberg K; Kallioniemi O; Aittokallio T
Article: BIOINFORMATICS. 2015;31(23):3815-3821
Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data
Mpindi J-P; Swapnil P; Dmitrii B; Jani S; Saeed K; Wennerberg K; Aittokallio T; Ostling P; Kallioniemi O
Article: NATURE. 2015;519(7541):102-105
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Article: CANCER DISCOVERY. 2013;3(12):1416-1429
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JML; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K